Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Leukemia 2Burkitt Lymphoma 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasm, Residual 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hypereosinophilic Syndrome 1Hematologic Diseases 1Head and Neck Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Dermatofibrosarcoma 1Congenital Bone Marrow Failure Syndromes 1Chordoma 1Carcinoma, Adenoid Cystic 1Blast Crisis 1

Interventions

Imatinib Mesylate 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Decitabine 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Bone Marrow Failure Syndromes × Imatinib Mesylate × 90 days × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡